Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Oct 26:13:199.
doi: 10.1186/1745-6215-13-199.

Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

Lena Schiffer  1 , Mario Schiffer, Saskia Merkel, Anke Schwarz, Michael Mengel, Christopher Jürgens, Christoph Schroeder, Alexander A Zoerner, Kerstin Püllmann, Verena Bröcker, Jan U Becker, Maximilian E Dämmrich, Jana Träder, Anika Grosshennig, Frank Biertz, Hermann Haller, Armin Koch, Wilfried Gwinner
Affiliations
Clinical Trial

Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

Lena Schiffer et al. Trials. .

Abstract

Background: Acute kidney allograft rejection is a major cause for declining graft function and has a negative impact on the long-term graft survival. The majority (90%) of acute rejections are T-cell mediated and, therefore, the anti-rejection therapy targets T-cell-mediated mechanisms of the rejection process. However, there is increasing evidence that intragraft B-cells are also important in the T-cell-mediated rejections. First, a significant proportion of patients with acute T-cell-mediated rejection have B-cells present in the infiltrates. Second, the outcome of these patients is inferior, which has been related to an inferior response to the conventional anti-rejection therapy. Third, treatment of these patients with an anti-CD20 antibody (rituximab) improves the allograft outcome as reported in single case observations and in one small study. Despite the promise of these observations, solid evidence is required before incorporating this treatment option into a general treatment recommendation.

Methods/design: The RIACT study is designed as a randomized, double-blind, placebo-controlled, parallel group multicenter Phase III study. The study examines whether rituximab, in addition to the standard treatment with steroid-boli, leads to an improved one-year kidney allograft function, compared to the standard treatment alone in patients with acute T-cell mediated tubulointerstitial rejection and significant B-cell infiltrates in their biopsies. A total of 180 patients will be recruited.

Discussion: It is important to clarify the relevance of anti-B cell targeting in T-cell mediated rejection and answer the question whether this novel concept should be incorporated in the conventional anti-rejection therapy.

Trial registration: Clinical trials gov. number: NCT01117662.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the study design of the RIACT study. Independent from the study protocol, all patients will receive steroid boli for rejection therapy.
See this image and copyright information in PMC

References

    1. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155. - PubMed
    1. Webster A, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev. 2006;2:CD004756. - PubMed
    1. Massy ZA, Guijarro C, Kasiske BL. Clinical predictors of chronic renal allograft rejection. Kidney Int Suppl. 1995;52:S85–S88. - PubMed
    1. Nickerson P, Jeffery J, Gough J, McKenna R, Grimm P, Cheang M, Rush D. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol. 1998;9:482–487. - PubMed
    1. Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int. 2002;61:727–733. doi: 10.1046/j.1523-1755.2002.00174.x. - DOI - PubMed

Publication types

Associated data